EP2167472A2 - 1-benzylpyrazole derivatives, preparation thereof and therapeutic use thereof - Google Patents

Abstract

The invention relates to compounds of the formula (I) in which: Y is a group selected from N(R7)CO-, -N(R7)CO-N(R7)-, -OCO-, -N(R7)S(O)n-; R1 is a hydrogen atom or a (C1-C4)alkyl group; R6 is a group selected from a (C1-C6)alkyl group, phenyl, benzyl or benzohydryl, a heterocyclic radical, a carbocyclic radical, a C3-C7)cycloalkylmethyl group; said salts being in state of a base or addition salts to an acid. The invention also relates to methods for preparing compounds of the formula (I) and to the use thereof as CB2 receptor antagonists that can cross the intestinal barrier for the treatment for autoimmune disorders, pain, gastrointestinal disorders, cardiovascular disorders and cancer.

Description

 DERIVATIVES OF 1-BENZYLP YRAZOLE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION

The present invention relates to 1-benzylpyrazole derivatives, to their preparation and to their therapeutic application.

1-Benzylpyrazole derivatives are known in the literature, in particular European Patent EP-B-868,420 and its US equivalent US 5,925,768 describe compounds of formula:

These compounds have affinity for human CB2 receptors. The patent application FR 2,887,550 describes compounds of formula:

which are CB2 cannabinoid receptor ligands. CB2 cannabinoid receptor antagonist compounds have now been found which exhibit a good passage of the intestinal barrier.

The subject of the present invention is compounds corresponding to formula (I): in which :

Y represents a group chosen from: i) -N (R ₇ ) CO-, ii) -N (R ₇ ) CO-N (R ₇ ) -, iii) -OCO-, iv) -N (R ₇ ) S (O) _n -;

K 1 represents a hydrogen atom or a (C 1 -C 4) alkyl group;

R2 and R4 each independently represent a hydrogen or halogen atom, a (C1-C4) alkyl, (C1-C4) alkoxy or trifluoromethyl group;

R 3 and R 5 are each independently of one another a halogen atom or a (C 1 -C 4) alkyl, (C 1 -C 4) alkoxy, trifluoromethyl, trifluoromethoxy, cyano or S (O) 1 _n Alk group;

Rg represents a group chosen from:

. a (C 1 -C 8) alkyl group which is unsubstituted or substituted one or more times with one or more substituents chosen independently from a halogen atom or a hydroxy, (C 1 -C 4) alkoxy or trifluoromethoxy group;

. phenyl which is unsubstituted or substituted one or more times with Rg;

. benzyl or benzhydryl;

. a heterocyclic radical chosen from: thienyl, furyl or pyrrolyl, said radicals being unsubstituted or substituted by a halogen atom, a group

(C 1 -C 4) alkyl or trifluoromethyl;

. a non-aromatic carbocyclic radical of C 1 -C 2, which is unsubstituted or substituted one or more times by a halogen atom or a (C 1 -C 4) alkyl group,

C4) alkoxy, hydroxy or cyano;

. a (C ₃ -C ₇ ) cycloalkylmethyl group, unsubstituted or substituted on the cycloalkyl by one or more (C 1 -C 4) alkyl groups;

. an aryloxymethyl group unsubstituted or substituted on the methyl by one or two alkyl groups, wherein the term aryloxy represents a phenoxy group unsubstituted or substituted one or more times with Rg;

R ₇ represents a hydrogen atom or a (C 1 -C 4) alkyl group; - Rg represents a halogen atom; a (C 1 -C 4) alkyl group; trifluoromethyl; cyano; (C1-C4) alkoxy; trifluoromethoxy; phenyl; (Cβ-Cγ) clcycloalkyl or NHS (O) _n Alk;

n represents 1 or 2; m represents 0, 1 or 2;

Alk represents a (C 1 -C 4) alkyl.

The compounds of formula (I) may exist in the form of bases or addition salts with acids. Such addition salts are part of the invention.

These salts are advantageously prepared with pharmaceutically acceptable acids, but the salts of other acids that are useful, for example, for the purification or the isolation of the compounds of formula (I) are also part of the invention.

The compounds of formula (I) may also exist in the form of hydrates or solvates, namely in the form of associations or combinations with one or more molecules of water or with solvent. Such hydrates and solvates are also part of the invention.

In addition, the compounds of formulas (I) according to the invention, as such or in radio-labeled form can be used as pharmacological tools in humans or animals for the detection and labeling of CB ₂ cannabinoid receptors. There may be mentioned in particular compounds (I) having one or more labeled atoms chosen from ³ H, ¹¹ C, ¹⁴ C, ¹⁸ F, ³⁵ S, ⁷⁶ Br, ¹²³ 1, ¹²⁵ I, and ¹³¹ I.

The compounds of formula (I) may comprise one or more asymmetric carbon atoms. They can therefore exist as enantiomers or diastereoisomers. These enantiomers, diastereoisomers, as well as their mixtures, including the racemic mixtures, form part of the invention. In the context of the present invention, the following terms mean:

a halogen atom: a fluorine, a chlorine, a bromine or an iodine, chlorine and fluorine being preferred;

a (C 1 -C 4) alkyl or (C 1 -C 8) alkyl group: a linear or branched saturated aliphatic group, for example, C 1 -C 4 or C 1 -C 6. By way of examples, mention may be made of methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl and tert-butyl groups, as well as pentyl, isopentyl, hexyl and isohexyl groups, for (C) -alkyl groups. ^ -Cg);

a (C 1 -C 4) alkoxy group: an O-alkyl radical in which the alkyl group is as previously described; a non-aromatic C 3 -C 12 carbocyclic radical ^: a monocyclic radical or a di- or tricyclic radical condensed or bridged; by monocyclic radical means cycloalkyl, that is to say a cyclic alkyl group for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentyl, cyclohexyl and cycloheptyl radicals being preferred; the term "condensed or bridged di- or tricyclic radical" is understood to mean, for example, bicyclo [2.2.1] heptyl, bicyclo [2.2.2] octanyl, bicyclo [3.2.1] octanyl, adamantyl.

Within the compounds of formula (I) according to the invention, there are:

compounds of formula (IA) in which Y represents a group -N (Ry) CO-;

compounds of formula (IB) in which Y represents a group - N (R ₇ ) CON (R ₇ ) -; compounds of formula (IC) in which Y represents a group -OCO-;

compounds of formula (ID) in which Y represents a group -N (R ₇ ) S (O) _n -.

Among the compounds of formula (I) which are the subject of the invention, mention may be made of the preferred compounds which are defined as follows:

K 1 represents hydrogen; R2 and R3 represent a 3 or 4-chlorine atom, a 4-trifluoromethyl group, or two 3 and 4-chlorine atoms;

- R4 and R5 represent a chlorine atom in 2, 3 or 4, a trifluoromethyl group in

4, or a chlorine atom at 3 and a methyl group at 4.

Of the 4 families of compounds, those of formula (IA) and of formula (ID) are preferred.

Within the compounds of formulas (IA) and (ID), the compounds whose substituents have the following definitions are preferred:

- R \ represents hydrogen;

R2 and R3 represent a 3 or 4-chlorine atom, a 4-trifluoromethyl group, or two 3 and 4-chlorine atoms;

- R4 and R5 represent a chlorine atom in 2, 3 or 4, a trifluoromethyl group in

4, or a chlorine atom at 3 and a methyl group at 4.

Rg represents a group chosen from:

. a (C 1 -C 6) alkyl group unsubstituted or substituted one or more times with one or more substituents independently selected from a halogen atom or a hydroxy, (C 1 -C 4) alkoxy or trifluoromethoxy group;

. a non-aromatic carbocyclic radical, _C3-Ci2> ^{No. n} unsubstituted or substituted one or more times with a halogen atom or a (Ci-C 4) alkyl, (C \ -

C4) alkoxy, hydroxy or cyano. In particular, the following compounds are preferred: N - ((1- (3,4-dichlorobenzyl) -5- (3,4-dichlorophenyl) -1H-pyrazol-3-yl) methyl)

2,2-dimethylpropanamide.

and N - ((1- (3,4-dichlorobenzyl) -5- (3,4-dichlorophenyl) -1H-pyrazol-3-yl) methyl)

2-methyl-2-sulfonamide.

According to the invention, the compounds of formula (I) can be prepared according to the following process. This process is characterized in that: a compound of formula

in which X represents an oxygen atom, an NH or N (R 1) and K 1 group,

R 2, R 3, R 4, R 5 are as defined above for the compounds of formula (I): a) with a functional derivative of an acid of formula R 6 COOH (III) in which R 6 is as defined herein above for (I) to obtain a compound of formula (IA) or (IC) in which Y represents the value i) or ii); b) an isocyanate of the formula RgN = C = O (IV) in which Rg is as defined above for (I), to obtain a compound of formula (IB) in which Y represents the value ii). c) with a halogenated derivative of formula RgS (O) _n HaI in which HaI represents a halogen atom, preferentially chlorine, and Rg is as defined above for (I), to obtain a compound of formula ( ID) in which Y has the value iv).

From a compound of formula (ID) in which Y = -N (Ry) SO-, a compound of formula (ID) in which Y = -N (Ry) Sθ2- can be prepared by oxidation, for example by action of metachloroperbenzoic acid.

By functional derivative of an acid of formula RgCOOH is meant an acid chloride, an anhydride or the free acid suitably activated for example with benzotriazol-1-yloxytris (dimethylamino) phosphonium hexafluorophosphate (BOP) or the dicyclohexylcarbodiimide (DCC).

Compounds of formula (I) in which Y represents a group -N (Ry) CO- or

-N (Ry) CON (Ry) - can be prepared from the corresponding compounds of formula (I) in which Y represents a group -NHCO- or -NHCONH- by a method chosen from methods known to the man of the 'art. Of these, one mention may be made of alkylation with a methyl halide or the formation of a carbamate by the action of ethyl chloroformate followed by a reduction by LiAlHφ

According to a variant of the process of the invention, the compounds of formula (Ig) can be obtained by a process characterized in that: a) a compound of formula (II) is treated with an ester of formula HaICOOAr (V) in which HaI represents a halogen atom and Ar represents an aryl group such as, for example, phenyl or 4-nitrophenyl; c2) the carbamate thus obtained of formula:

by an amine of formula: R5R7NH (VII) in which R8 and R7 are as defined for a compound of formula (IB).

Step a) is carried out in an aprotic solvent such as dichloromethane, THF or DMF at a temperature between 0 ° C. and the boiling point of the solvent.

Step b) is carried out in a solvent such as dichloromethane at room temperature.

Step c1) is carried out in an aprotic solvent such as dichloromethane at room temperature.

Step c2) is carried out in an aprotic solvent such as dichloromethane at a temperature between room temperature and the boiling point of the solvent.

The compounds of formula (II) are prepared according to the following reaction scheme:

SCHEME 1

HaI: halogen atom, preferentially Cl or Br.

When X represents an NH group, the compound of formula (II) is represented by the compound of formula (XI).

When X represents an oxygen atom, the compound of formula (II) is represented by the compound of formula (IX).

In the first step (a _t ), the ester of formula (VIII) is reduced by the action of a reducing agent such as LiAlH-; .

In the next step (a ₂ ), the hydroxymethyl derivative (IX) obtained is treated with an agent such as PCI5, PBrc, HBr or BBr3 to form the halomethylated derivative of formula (X).

Finally, the compound of formula (XI) is obtained during step (a ₃ ) by treating the

The compound of formula (X) is successively 1,3,5,7-tetraazatricyclo [3.3.1] decane (or hexamethylenetetramine) followed by a strong acid such as hydrochloric acid.

The compounds of formula (VIII) are obtained according to the method of preparation described in patent EP-B-868 420.

The compounds of formula (XI) are new. Thus the invention, according to another of its aspects, also relates to the compounds of formula (XII):

in which :

- W represents a hydroxyl or amino group;

R 1 represents a hydrogen atom or a C 1 -C 4 alkyl group;

R 2 and R 4 each independently represent a hydrogen or halogen atom, or a (C 1 -C 4) alkyl, (C 1 -C 4) alkoxy or trifluoromethyl group;

- R3 and R5 are each independently of one another a halogen atom or a (C1-C4) alkyl, (C1-C4) alkoxy or trifluoromethyl group;

The compounds of formula (XII) may exist in the form of bases or addition salts with acids. Such addition salts are part of the invention.

The compounds of formula (XII) may also exist in the form of hydrates or solvates, namely in the form of associations or combinations with one or more molecules of water or with solvent. Such hydrates and solvates are also part of the invention. These compounds are useful as synthesis intermediates for the compounds of formula (I) according to the invention.

Preferentially, the compounds of formula (XII) correspond to those whose substituents have the following definitions:

- Rj represents a hydrogen atom;

R2 and R3 represent a 3 or 4-chlorine atom, a 4-trifluoromethyl group, or two 3 and 4-chlorine atoms;

- R4 and R5 represent a chlorine atom in 2, 3 or 4, a trifluoromethyl group in 4, or a chlorine atom in 3 and a methyl group in 4.

Rg represents a group chosen from:

. a (C 1 -C 8) alkyl group which is unsubstituted or substituted one or more times with one or more substituents independently selected from a halogen atom or a hydroxy, (C 1 -C 6) alkoxy or trifluoromethoxy group; . a non-aromatic carbocyclic radical of C 1 -C 2, unsubstituted or substituted one or more times by a halogen atom or a (C ₁ -C ₄ ) alkyl, (C ₁ -C ₄ ) alkoxy, hydroxy or cyano group.

The following examples describe the preparation of certain compounds according to the invention. These examples are not limiting and only illustrate the present invention. The numbers of the compounds exemplified refer to those given in the table below, which illustrates the chemical structures and the physical properties of some compounds according to the invention.

In the examples, the following abbreviations are used: RT: room temperature

(dec.): decomposition TEA: triethylamine THF: tetrahydrofuran DMF: dimethylformamide DCM: dichloromethane

DMSO: dimethylsulfoxide

BOP: benzotriazol-1-yloxytris (dimethylamino) phosphonium / hexafluorophosphate

K ₂ SO ₄ / KHSO ₄ : buffer pH 2 (KHSO ₄ 0.12 M and K ₂ SO ₄ 0.185 M) AcOEt: ethyl acetate

PyBOP: benzotriazol-1-yloxytris (pyrrolidino) phosphonium hexafluorophosphate

LiHMDS: lithium salt of hexamethyldisilazane MeOH: methanol EtOH: ethanol

And ₂ O: ethyl ether AcOH: acetic acid F: melting temperature.

For nuclear magnetic resonance (NMR) spectra recorded at 200 MHz in DMSO-d _ό , the observed signals are expressed as follows: d: doublet; of: expanded doublet; d. of d. doublet of doublet; s: singlet; it is: widened singlet; t: triplet.

The compounds according to the invention are analyzed by LC / UV / MS coupling (liquid chromatography / UV detection / mass spectrometry). The molecular peak (MH) and the retention time (t) are measured in minutes. Conditions (A):

An Xterra Waters MS C 18 column, marketed by Waters, 2.1 x 30 mm, 3.5 μm, was used at ambient temperature, flow rate 1 mL / minute. The eluent is composed as follows:

solvent A: 0.025% trifluoroacetic acid (TFA) in water;

solvent B: 0.025% of TFA in acetonitrile.

Gradient: The percentage of solvent B varies from 0 to 100% in 2 minutes with a plateau at 100% of B for 1 minute.

The UV detection is carried out between 210 nm and 400 nm and the mass detection in chemical ionization mode at atmospheric pressure.

Conditions (B):

A Symmetry Cl 8 column of 2.1 x 50 mm, 3.5 μm, was used at 30 ° C, flow rate 0.4 mL / min.

The eluent is composed as follows: solvent A: 0.005% trifluoroacetic acid (TFA) in water at pH 3.15;

solvent B: 0.005% of TFA in acetonitrile.

Gradient:

Column temperature: 30 ° C, flow rate 0.4 ml / min.

The UV detection is carried out at λ = 210 nM and the chemical ionization mass detection (ESI of the English Electro Spray Ionization) positive.

Conditions (C):

A Symmetry Cl 8 column of 2.1 x 50 mm, 3.5 μm, was used at 30 ° C, flow rate 0.4 mL / min.

The eluent is composed as follows:

solvent A: 0.005% trifluoroacetic acid (TFA) in water at pH 3.1;

solvent B: 0.005% of TFA in acetonitrile. Gradient:

Column temperature: 30 ° C, flow rate 0.4 ml / min.

The UV detection is carried out at λ = 210 - 220 nM and the chemical ionization mass detection (ESI of English Electro Spray Ionization) positive.

Conditions (D):

An XTerra MS Cl 8 column of 2.1 x 50 mm, 3.5 μm, is used at 30 ° C., flow rate 0.4 ml / minute.

The eluent is composed as follows:

solvent A: 10 mM ammonium acetate in water at pH 7;

solvent B: acetonitrile

Gradient:

Column temperature: 30 ° C, flow rate 0.4 ml / min.

The UV detection is carried out at λ = 210 nM and the chemical ionization mass detection (ESI of the English Electro Spray Ionization) positive. EXAMPLE 1: Compound 19

N - ((1- (3-Chloro-4-methylbenzyl) -5- (3,4-dichlorophenyl) -1H-pyrazol-3-yl) methyl) -1-methylcyclohexanecarboxamide. A) (1- (3-chloro-4-methylbenzyl) -5- (3,4-dichlorophenyl) -1H-pyrazol-3-yl) methanol.

4 g of methyl 1- (3-chloro-4-methylbenzyl) 5- (3,4-dichlorophenyl) -1H-pyrazole-3-carboxylate are dissolved in 100 ml of THF and cooled to between 0 ° C. and -5 ° C. ° C. and then 0.6 g of LiAlH 4 are added in small portions while keeping at the same low temperature. It is allowed to return to RT and stir 30 minutes. It is hydrolyzed at 0 ° C. with N NaOH (100 ml). The mixture is filtered and the filtrate is washed with THF and evaporated. oil obtained is taken up in ether, washed with water, with NaCl solution, then dried over Na 2 SO 4 and evaporated to dryness to obtain 3.5 g of the expected compound.

NMR (200 MHz) in DMSOd ₆ : 7.7 ppm: d: 1H; 7.6 ppm: d: 1H; 7.4 ppm: d from d: 1H; 7.3 ppm: d: 1H; 7 ppm: d: 1H; 6.8 ppm: d from d: 1H; 6.4 ppm: s: 1H; 5.3 ppm: s: 2H; 5.1 ppm: t: 1H; 4.4 ppm: d: 2H; 2.2 ppm: s: 3H.

B) 3- (Chloromethyl) -1- (3-chloro-4-methylbenzyl) -5- (3,4-dichlorophenyl) -1H-pyrazole.

3.45 g of compound of the compound of the preceding step are dissolved in 100 ml of DCM. It is cooled by an ice bath and 1.96 g of PCI5 are added per fraction at a temperature below 10 ° C. The mixture is stirred for 3 hours at RT and then poured into a mixture of water and ice and stirring is continued for 3 hours. The mixture is left to settle and then the organic phase is washed with a Na deCO 3 solution and then with water. It is dried over Na 2 SO 4 and then evaporated to dryness. The oil obtained is purified by chromatography on silica eluting with AcOEt / cyclohexane (25/75, v / v). 2.35 g of the expected compound are obtained in the form of an oil which crystallizes. F = 88 ^° C.

C) (1- (3-Chloro-4-methylbenzyl) -5- (3,4-dichlorophenyl) -1H-pyrazol-3-yl) methanamine hydrochloride.

2.3 g of the compound of the preceding step are dissolved in 200 ml of CΗClI and 0.8 g of 1,3,5,7-tetraazatricyclo [3.3.1] decane are added. After stirring for 5 days at RT, 150 ml of ether are added, the precipitate formed is filtered off and then dissolved in

50 ml of ethanol. 2 ml of concentrated HCl are added and the mixture is heated at 50 ° C. for 3 hours. The medium is concentrated to half volume and then 50 ml of ether are added. It is filtered off, washed with ether and dried to obtain 1.78 g of the expected compound in base form.

To prepare the hydrochloride, it is dissolved in 50 ml of ethanol, 2 ml of concentrated HCl are added and the mixture is heated at 50 ° C. for 3 hours. The medium is concentrated under vacuum, drained and then washed with ether and dried to give 1.88 g of the expected hydrochloride. NMR (200 MHz) in DMSO-d ₆ : 8.6 ppm: SE: 1H; 7.7 ppm: d: 1H; 7.6 ppm: d: 1H; 7.4 ppm: d of d: 1H; 7.3 ppm: d: 1H; 7.1 ppm: d: 1H; 6.9 ppm: d from d: 1H; 6.7 ppm: s: 1H; 6 ppm: se: 2H; 5.4 ppm: s: 2H; 4 ppm: 2 d: 2H; 2.3 ppm: s: 3H.

D) N - ((1- (3-Chloro-4-methylbenzyl) -5- (3,4-dichlorophenyl) -1H-pyrazol-3-yl) methyl) -1-methylcyclohexanecarboxamide.

417 mg of the compound of the previous step, 142 mg of 1-methylcyclohexanecarboxylic acid and 580 mg of BOP in 50 ml of DMF are mixed and then triethylamine is added to reach pH 10.

It is left stirring for 20 hours at room temperature. The product obtained is purified by chromatography on silica eluting with a DCM / MeOH mixture (97.5 / 2.5, v / v). 250 mg of the expected compound are obtained, mp 63 ° C.

EXAMPLE 2: Compound 60 N-Ctert-Butyl-N '- (1-CS-chloro-methylbenzyl) -S-CS-dichlorophenyl-1H-pyrazol-3-yl) methyl) urea.

0.5 g of the compound obtained in step C of Example 1 are dissolved in 30 ml of DCM and 0.137 ml of 2-isocyanato-2-methylpropane and then a sufficient amount of triethylamine are added to reach pΗ9. The mixture is stirred at RT overnight. After adding 10 ml of water, decanted. The organic phase is washed successively with aqueous solutions of NaHCO 3, K 2 SO 4 / KHSO 4, and then water. It is dried over Na 2 SO 4 and then evaporated to dryness. The residue is taken up in an AcOEt / cyclohexane mixture (50/50, v / v). The expected compound precipitates in the form of a white solid: m = 360 mg, mp = 181 ° C. EXAMPLE 3: compound 46

N - ((1- (3-Chlorobenzyl) -5- (3,4-dichlorophenyl) -1H-pyrazol-3-yl) methyl) -2,2-dimethylpropanamide.

A) 1- (3,4-Dichlorophenyl) -4-methoxy-3,4-dioxobut-1-en-1-olate sodium.

A solution of sodium methylate is prepared by slowly introducing 23 g of sodium into 1 liter of methanol, cooling with an ice bath and adding

188.97 g of 1- (3,4-dichlorophenyl) ethanone followed by 149.14 g of ethyl oxalate in 250 ml of methanol. A precipitate forms. 500 ml of methanol are added and the mixture is left stirring for 2 hours. 500 ml of Et2θ are added and stirring is maintained

30 minutes. The precipitate formed is filtered and then dried to obtain 297 g of the expected compound.

B) Methyl 5- (3,4-dichlorophenyl) -1H-pyrazole-3-carboxylate.

123.43 g of the compound obtained in the preceding step are placed in 800 ml of AcOΗ, 25.60 ml of hydrazine hydrate are added dropwise and the mixture is heated overnight under reflux. The reaction medium is poured into ice water. The precipitate formed is drained and washed with water. It is taken up in Et 2 O, the organic phase is washed with saturated NaCl solution and then dried over Na 2 SO 4, evaporated and filtered. 91.85 g of the expected compound are obtained.

C) 1- (3-Chlorophenyl) -5- (3,4-dichlorophenyl) -1H-pyrazole-3-carboxylic acid methyl ester. 14.50 g of the compound obtained in the preceding step are placed in 250 ml of toluene and 2.35 g of NaH are added by pinch and then heated at 65 ° C. for 1 hour. We cooled to RT and 7.72 ml of 3-chlorobenzyl bromide was slowly added. The reaction medium is refluxed for 20 hours and then neutralized with a saturated solution of NH 4 Cl. The organic phase is allowed to settle and then washed with saturated NaCl solution. It is dried over Na 2 SO 4 and then evaporated. The product obtained is dissolved in AcOEt and then washed with saturated NaHCO3 solution, K2SO4 / KHSO4 solution and water. It is dried over Na 2 SO 4 and evaporated to obtain 64.37 g of the expected compound.

D) 1- (1- (3-Chlorobenzyl) -5- (3,4-dichlorophenyl) -1H-pyrazol-3-yl) methanol.

24.26 g of the compound obtained in the preceding step are dissolved in 500 ml of THF under a nitrogen atmosphere and cooled to -5 ° C. 1.47 g of LiAlH 4 are added in small portions at a temperature below 0 ° C. It is allowed to return to RT and then stirred for 1 hour. The reaction medium is hydrolysed at 0 ° C. with 1N NaOH. After filtration, the insoluble material is washed with THF. The filtrates are combined and evaporated to dryness and the residue is taken up with ether. This organic phase is washed with a saturated solution of NaCl and then dried over Na 2 SO 4 and evaporated to dryness. The product obtained is purified by chromatography on silica eluting with an AcOEt / cyclohexane mixture (50/50, v / v).

6.82 g of the expected compound are obtained, mp = 95 ° C.

E) 1- (3-Chlorobenzyl) -3- (chloromethyl) -5- (3,4-dichlorophenyl) -1H-pyrazole.

6.7 g of the compound obtained in the previous step are dissolved in 200 ml of DCM and cooled between 0 ° C. and -10 ° C. 3.98 g of PCI5 are then added dropwise at -10 ° C. and the mixture is left stirring for 4 hours at RT. The reaction medium is poured onto ice and left overnight. The organic phase is decanted and then extracted again with 50 ml of DCM. The extracts are collected, dried over Na 2 SO 4 and evaporated to dryness. 7.41 g of the expected compound is obtained. F) 1- (1- (3-Chlorophenyl) -5- (3,4-dichlorophenyl) -1H-pyrazol-3-yl) methanamine hydrochloride. 7.3 g of the compound obtained in the previous step are dissolved in 500 ml of

Chloroform and 2.65 g of 1,3,5,7-tetraazatricyclo [3.3.1] decane are added. After stirring for 5 days, 500 ml of ether are added. After 2 hours, the precipitate formed is filtered off. The product obtained is dissolved in 50 ml of EtOH and 2 ml of concentrated HCl are then added and the mixture is heated at 60 ^° C. for 3 hours. It is evaporated to dryness and then taken up in hydrochloric ether. The precipitate formed is drained and then dried to give 4.67 g of the expected compound. Mp = 150 ° C. G) N - ((1- (3-Chlorobenzyl) -5- (3,4-dichlorophenyl) -1H-pyrazol-3-yl) methyl) -2,2-dimethylpropanamide. 0.6 g of the compound obtained in the preceding step and 0.18 g of pivalic acid are dissolved in 50 ml of DMF, then 0.92 g of PyBOP and 0.45 ml of triethylamine are added and a suspension is stirred. night at TA. The DMF is evaporated and then taken up with AcOEt. A solution of K 2 SO 4 / KHSO 4 and then water are washed with a saturated solution of NaHCO 3; it is dried over Na 2 SO 4 and then evaporated to dryness. The product obtained is purified by chromatography on silica eluting with a DCM / MeOH mixture (95/5, v / v). 0.31 g of the expected compound is obtained.

NMR: 1.12 ppm: s: 9H; 4.25 ppm: d: 2H; 5.34 ppm: s: 2H; 6.33 ppm: s: 1H; 6.85-7.45 ppm: m: 5H; 7.61 ppm: d: 1H; 7.71 ppm: d: 1H; 7.98 ppm: t: 1H.

EXAMPLE 4: Compound No. 55

(1- (3,4-Dichlorobenzyl) -5- (4-trifluoromethylphenyl) -1H-pyrazol-3-yl) methyl pivalate.

A) Lithium 1- (4- (trifluoromethylphenyl) -4-ethoxy-3,4-dioxobut-1-en-1-olate 24.45 g of LiΗMDS are dissolved in 100 ml of THF under a nitrogen atmosphere. anhydrous and cooled to -60 ^° C. In addition, 25 g of 1- (4-trifluoromethylphenyl) ethanone are dissolved in 50 ml of Et 2 O. The ketone solution is introduced dropwise into the LiHMDS solution at -60.degree. ^{0 °} C., then the temperature is allowed to rise to -30 ° C. and 19.85 ml of diethyl oxalate are rapidly added, the mixture is then evaporated to dryness overnight and the residue is evaporated to dryness and the residue is taken up in ether. The precipitate formed is drained, washed with ether and then dried to give 33.28 g of the expected compound.

B) Ethyl 5- (4-trifluoromethylphenyl) -1H-pyrazol-3-carboxylate.

33.2 g of the compound obtained in the preceding step are dissolved in 400 ml of AcOΗ and 6.33 ml of hydrazine hydrate are added dropwise and the mixture is refluxed for 5 hours with stirring. After 1 night at RT, the medium is poured into ice water and the precipitate formed is filtered off after 1 hour. Wash with water and dry, then resume with DCM. It is dried over Na 2 SO 4 and evaporated to dryness. 30.37 g of the expected compound are obtained. C) 1- (3,4-Dichlorobenzyl) -5- (4-trifluoromethylphenyl) -1H-pyrazole-3-carboxylic acid ethyl ester.

From 30.3 g of the compound obtained in the preceding step, this compound is prepared according to the method described in Example 3, step C. 36.24 g of the expected compound are obtained. D) 1- (1- (3,4-Dichlorobenzyl) -5- (4-trifluoromethylphenyl) -1H-pyrazol-3-ylmethanol. This compound is prepared following the method described in Example 3, step D. From 33 g of the compound of the preceding step, 23.10 g of the expected compound are obtained. F = 96 ^° C. 1- (3,4-dichlorobenzyl) -5- (4-trifluoromethylphenyl) -1H-pyrazol-3-yl) methyl.

1 g of the compound obtained in the previous step is dissolved in 50 ml of DMF. 0.37 ml of pivaloyl chloride and then 0.52 ml of triethylamine are added and the mixture is stirred at RT for 20 hours. The solvent is evaporated under vacuum and then taken up in 50 ml of AcOEt. It is washed with a saturated solution of NaΗCθ3 then with K2SO4 / KHSO4 then with a saturated solution of NaCl. It is dried over Na 2 SO 4 and then evaporated to dryness. The product obtained is purified by chromatography on silica eluting with an AcOEt / cyclohexane mixture (25/75; v / v). 0.89 g of the expected compound is obtained in the form of an oil which crystallizes, mp = 92 ° C.

By proceeding as in step C) of Example 1, the intermediate compounds described in Table 1 below are prepared. When the compound is characterized by LC / UV / MS, the operating conditions (A), (B), (C) or (D) are specified.

TABLE 1

EXAMPLE 5 Compound No. 60

N - ((1- (3,4-dichlorobenzyl) -5- (3,4-dichlorophenyl) -1H-pyrazol-3-yl) methyl) -2,2-dimethylpropanamide.

0.50 g of 1- (1- (3,4-dichlorobenzyl) -5- (3,4-dichlorophenyl) -1H-pyrazol-3-yl) methanamine, as described in Table I, is placed in place and 0.15 g of pivaloic acid in 50 ml of DMF in the presence of 0.68 g of PyBOP and 0.28 ml of TEA are added. After stirring overnight at room temperature, the solvent is evaporated and then taken up with AcOEt, washed with a saturated solution of NaHCO ₃ and then with K ₂ SO ₄ / KHSO ₄ . Dry over Na ₂ SO ₄ and evaporate to dryness. It is purified by chromatography on silica eluting with an AcOEt / cyclohexane mixture (50/50, v / v). 0.36 g of the expected compound is obtained. M.p. 56.5 ° C.

NMR: 1.09 ppm: s: 9H; 4.23 ppm: d: 2H; 5.32 ppm: se: 2H; 6.31 ppm: s: 1H; 6.96 ppm: d. of d. : IH; 7.27 ppm: d: 1H; 7.61 ppm: d: 1H; 7.69 ppm: d: 1H; 7.95 ppm: t: 1H. EXAMPLE 6 Compound No. 89

N - ((1- (3,4-dichlorobenzyl) -5- (3,4-dichlorophenyl) -1H-pyrazol-3-yl) methyl) -2-methylpropane-2-sulfinamide.

1.2 g of 1- (1- (3,4-dichlorobenzyl) -5- (3,4-dichlorophenyl) -1H-pyrazol-3-yl) methanamine, described in Table I, and 0.44 ml are placed. of 2-methylpropane chloride 2-sulphinyl in 50 ml of DMF and 1.24 ml of TEA are added. The mixture is stirred for 16 hours. The solvent is evaporated and then purified by chromatography on silica eluting with cyclohexane and then a cyclohexane / AcOEt gradient from 99/1 to 70/30. 0.85 g of the expected compound is obtained.

NMR: 1.12 ppm: s: 9H; 4.15 ppm: m: 2H; 5.37 ppm: s: 2H; 5.71 ppm: t, 1H; 6.52 ppm: s: 1H; 6.99 ppm: d from d: 1H; 7.27 ppm: d: 1H; 7.36 ppm: d from d: 1H; 7.57 ppm: d: 1H; 7.63 ppm: d: 1H; 7.72 ppm: d: 1H. EXAMPLE 7 Compound No. 90 N - ((1- (3,4-dichlorobenzyl) -5- (3,4-dichlorophenyl) -1H-pyrazol-3-yl) methyl) -2-methylpropane-2-sulfonamide.

0.68 g of metachloroperbenzoic acid are dissolved in 55 ml of DCM and the mixture is cooled to between 0 ° C. and -5 ° C. and 0.55 g of the compound obtained in the preceding example is then added to 5 ml of DCM. Allowed to warm to room temperature and stirred overnight. The reaction medium is poured into 50 ml of 1N NaOH and decanted. The organic phase is washed with water and then dried and evaporated to dryness. Purified by chromatography on silica eluting with cyclohexane and then a cyclohexane / AcOEt gradient of 99/1 to 50/50 in 1 hour. 0.39 g of the expected compound is obtained. M.p. 127.4 ° C.

NMR: 1.27 ppm: s: 9H; 4.22 ppm: d: 2H; 5.37 ppm: se: 2H; 6.50 ppm: s: 1H; 6.97 ppm: d from d: 1H; 7.28 ppm: d: 1H; 7.36 ppm: d from: 1H; 7.46 ppm: t: 1H; 7.56 ppm: d: 1H; 7.63 ppm: d: 1H; 7.72 ppm: d: 1H.

The following tables illustrate the chemical structures and the physical properties of some compounds according to the invention. In the tables, Me, Et, iPr and tBu respectively represent the methyl, ethyl, isopropyl and tert-butyl groups. When the compound is characterized by LC / UV / MS, the operating conditions (A), (B), (C) or (D) are specified.

TABLE 2

NMR: Compound 30: 1.0 ppm: s: 9H; 4.1 ppm: d: 2H; 5.2 ppm: s: 2H; 6.2 ppm: s: 1H; 6.9 ppm: d. of d. : IH; 7.1 ppm: d: 1H; 7.2-7.6 ppm: m: 5H; 7.9 ppm: t: 1H.

NMR: Compound 33: 1.0 ppm: s: 9H; 4.2 ppm: d: 2H; 5.2 ppm: s: 2H; 6.2 ppm: s: 1H; 6.9 ppm: d: 2H; 7.2 ppm: m: 3H; 7.5 ppm d: 1H; 7.6 ppm: d: 1H; 7.9 ppm: t: 1H.

NMR: Compound 34: 1.0-1.6 ppm: m: 1H; 1.8-2.1 ppm: d: 2H; 4.2 ppm: d: 2H; 5.3 ppm: s: 2H; 6.2 ppm: s: 1H; 7.0 ppm: d: 2H; 7.4 ppm: m: 3H; 7.6 ppm: d: 1H; 7.7 ppm: d: 1H; 8.0 ppm: t: 1H. TABLE 3

TABLE 4 TABLE 5

The compounds of formula (I) have a very good in vitro affinity for cannabinoid CB2 receptors, whether they are human receptors or rodent receptors. Affinity binding (binding) assays were performed with membranes derived from rodent tissues and cell lines in which CB2 receptors (Munro et al., Nature 1993, 365, 61-65) were expressed, according to experimental conditions described by M. Rinaldi-Carmona in J. Pharmacol. Exp. Therap. 1998, 287, 644-650.

More particularly, the compounds of the present invention or their optional salts are strong and selective CB2 cannabinoid receptor ligands, having an IC ₅₀ (concentration causing a 50% inhibition of the specific binding of the control) generally between 0.1 and 50nM. They are typically between 10 and 1000 times more active on CB2 receptors than on CBj receptors. In addition, the antagonistic nature of the compounds of formula (I) has been demonstrated by the results obtained in the models of adenylate cyclase inhibition as described in M. Rinaldi-Carmona et al., J. Pharmacol. Exp. Ther. 1996, 278, 871-878 and 1998, 284, 644-650 and M Bouaboula et al., J. Biol Chem., 1997, 272,

22330-22339.

The compounds according to the invention have been studied on a model of the passage of the intestinal barrier constituted by Caco-2 cells. (MCGres, Pharm Res., 1998, 15 (5), 726-733). This model makes it possible to define the coefficient Ptot of apparent permeability of the product for the monolayer of intestinal epithelial cells plus filter. As examples, compounds No. 60 (ex.5) and No. 90 (ex.7) are respectively in this model a Ptot of 111.97 and 64.5 (10 ^{"cm sec.";} Concentration = 20 μM apical pH = 6.5 and basal pH = 7.4). These values are predictive of total absorption in humans after oral administration. Thus, according to another of these aspects, the invention relates to medicaments for human or veterinary medicine which comprise a compound of formula (I) or an addition salt thereof to a pharmaceutically acceptable acid or a hydrate or a solvate. The compounds according to the invention can be used in humans or animals (in particular in mammals including, but not limited to, dogs, cats, horses, cattle, sheep) in the treatment or prevention of diseases involving CB ₂ cannabinoid receptors.

These drugs find their therapeutic use in the treatment or prevention of pathologies involving the cells of the immune system or immune disorders, for example autoimmune diseases, diseases associated with organ transplants, infectious diseases, allergic diseases, diseases of the gastrointestinal system, diseases of inflammatory origin. More particularly, mention may be made of the following autoimmune diseases: systemic lupus erythematosus, connective tissue diseases or connective tissue diseases, Sjögren's syndrome, ankylosing spondylitis, reactive arthritis, rheumatoid arthritis, undifferentiated spondyloarthritis, Behcet, hemolytic autoimmune anemias, multiple sclerosis, amyotrophic lateral sclerosis (Charcot's disease), psoriasis. The allergic diseases to be treated may be of the immediate hypersensitivity type or asthma, allergic rhinitis, allergic conjunctivitis or contact dermatitis. Similarly, the compounds and their possible pharmaceutically acceptable salts can be used to treat vascularity, parasitic infections, viral infections (AIDS), bacterial infections (meningitis), amyloidosis, diseases affecting lymphohematopoietic system lineages.

The compounds of formula (I) according to the invention can be used as a medicament in the treatment or prevention of pain: neuropathic pain, acute peripheral pain, chronic pain of inflammatory origin. The following inflammatory diseases can be mentioned: arthritis, rheumatoid arthritis, osteoathritis, spondylitis, gout, Crohn's disease, ulcerative colitis, irritable bowel disease (IBS) or inflamed (IBD) ), acute pancreatitis. The compounds of formula (I) may also be used in the treatment of bone diseases and osteoporosis.

In addition, the compounds of formula (I) according to the invention may be used as a medicament in the treatment or prevention of gastrointestinal disorders, diarrheal disorders, ulcers, vomiting, bladder and urinary disorders, renal disorders, renal ischemia, nephritis, endocrine disorders, cardiovascular disorders, hemorrhagic shock, septic shock, chronic cirrhosis of the liver, asthma, Raynaud's disease , glaucoma, fertility disorders, and as a drug for cancer chemotherapy (cancer of the skin, prostate or brain). The compounds of formula (I) according to the invention can be used as a medicament for the treatment of appetite disorders and / or eating behaviors, in particular for the treatment of cachexia. The compounds of formula (I) according to the invention can be used as a medicament for the prevention and / or treatment of obesity and associated cardio-metabolic diseases (hypertension, dyslipedimia, atherosclerosis) metabolic syndrome, resistance to 'insulin

(type 2 diabetes) and metabolic steatohepatopathy.

In addition, the compounds of formula (I) may be useful as a neuroprotector, in the treatment of ischemia, head trauma and the treatment of neurodegenerative diseases: including chorea, Huntington's disease, Tourrette.

The compound of formula (I) according to the invention can be used as a medicament for the treatment or prevention of migraine, stress, psychosomatic diseases, panic attacks, epilepsy, movement disorders. The compounds of formula (I) according to the invention may be used as a medicament in the treatment or prevention of diseases of the respiratory system such as chronic bronchitis, chronic obstructive bronchitis (COPD) or emphysema.

Thus the compounds of formula (I) according to the present invention are particularly useful for the preparation of medicaments for the treatment and prevention of immune disorders, pain, gastrointestinal disorders, cardiovascular or renal disorders, and or useful in cancer chemotherapy.

According to another of its aspects, the present invention relates to pharmaceutical compositions comprising, as active ingredient, at least one compound of formula (I) according to the invention. These pharmaceutical compositions contain an effective dose of a compound according to the invention, or a pharmaceutically acceptable salt, a hydrate or solvate of said compound, as well as one or more pharmaceutically acceptable excipients.

Said excipients are chosen according to the pharmaceutical form and the desired mode of administration, from the usual excipients which are known to those skilled in the art.

In addition to a compound of formula (I) or its pharmaceutically acceptable salts or hydrates or solvates, the pharmaceutical compositions according to the present invention may comprise one or more other active ingredients that are useful in the treatment or prevention of the pathologies indicated above. .

Thus, the subject of the present invention is also pharmaceutical compositions comprising a compound of formula (I) according to the present invention combined with one (or more) active principle chosen from one of the following therapeutic classes: an antagonist and / or modulator and / or CB1 receptor inverse agonist to cannabinoids;

another antagonist and / or modulator and / or inverse agonist of CB2 cannabinoid receptors;

an antagonist of AT ₁ receptors for angiotensin II; an inhibitor of the conversion enzyme;

a calcium antagonist;

- a diuretic;

a beta-blocker;

an antidepressant, an antispychotic, an anxiolytic; an anticancer agent or an antiproliferative agent;

an opioid antagonist; as well as :

an agent improving the memory;

an agent useful in the treatment of alcoholism or withdrawal symptoms;

a useful agent for treating osteoporosis; a useful agent for treating autoimmune diseases;

an agent useful for treating organ transplant rejections;

a nonsteroidal or steroidal anti-inflammatory drug;

an anti-infective agent;

- an anti-parasitic; an anti-viral;

- an analgesic;

- an anti-diarrhea;

- an antiasthmatic.

According to another aspect of the invention, the compound of formula (I), or one of its solvates or hydrates and the other associated active ingredient can be administered simultaneously, separately or spread over time.

By "simultaneous use" is meant the administration of the compounds of the composition according to the invention included in one and the same pharmaceutical form.

By "separate use" is meant the administration, at the same time, of the two compounds of the composition according to the invention each included in a separate pharmaceutical form.

By "use spread over time" is meant the successive administration of the first compound of the composition of the invention, included in a pharmaceutical form, and then the second compound of the composition according to the invention, included in a pharmaceutical form. separate. In this case, the lapse of time elapsing between the administration of the first compound of the composition according to the invention and the administration of the second compound of the same composition according to the invention generally does not exceed 24 hours.

In the pharmaceutical compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration, the active ingredient of formula (I) above, or its Any salt, solvate or hydrate may be administered in unit dosage form, in admixture with conventional pharmaceutical excipients, to animals and humans for the prophylaxis or treatment of the above disorders or diseases. Suitable unit dosage forms include oral forms such as tablets, soft or hard capsules, powders, granules and oral solutions or suspensions, sublingual, oral, intratracheal, intraocular, intranasal forms of administration. by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms and implants. For topical application, the compounds according to the invention can be used in creams, ointments or lotions.

By way of example, a unitary form of administration of a compound according to the invention in tablet form may comprise the following components:

Compound according to the invention 50.0 mg Mannitol 223.75 mg

Croscarmellose sodium 6.0 mg Corn starch 15.0 mg Hydroxypropyl methylcellulose 2.25 mg

Magnesium stearate 3.0 mg

Orally, the dose of active ingredient administered per day can reach 0.01 to 100 mg / kg, in one or more doses, preferably from 0.1 to 50 mg / kg.

There may be special cases where higher or lower dosages are appropriate; such dosages are not outside the scope of the invention. According to the usual practice, the dosage appropriate to each patient is determined by the physician according to the mode of administration, the weight and the response of said patient.

The present invention, according to another of its aspects, also relates to a method of treatment of the pathologies indicated above which comprises the administration to a patient of an effective dose of a compound according to the invention, or of one of its pharmaceutically acceptable salts or hydrates or solvates.

Claims

1. Compounds corresponding to formula (I):

in which :

Y represents a group chosen from: i) -N (R ₇ ) CO-, ii) -N (R ₇ ) CO-N (R ₇ ) -, iii) -OCO-, Iv) -N (R ₇ ) S (O) _n -;

R 1 represents a hydrogen atom or a (C 1 -C 4) alkyl group;

R 2 and R 4 each independently represent a hydrogen or halogen atom, or a (C 1 -C 4) alkyl, (C 1 -C 4) alkoxy or trifluoromethyl group, R 3 and R 5 represent each independently of one another a halogen atom or a (C 1 -C 4) alkyl, (C 1 -C 4) alkoxy, trifluoromethyl, trifluoromethoxy, cyano or S (O) 1 _n Alk group;

Rg represents a group chosen from:

. a (C 1 -C 6) alkyl group which is unsubstituted or substituted one or more times with one or more substituents independently selected from a halogen atom or a hydroxy, (C 1 -C 4) alkoxy or trifluoromethoxy group;

. phenyl which is unsubstituted or substituted one or more times with Rg;

. benzyl or benzhydryl;

. a heterocyclic radical chosen from: thienyl, furyl or pyrrolyl, said radicals being unsubstituted or substituted by a halogen atom, a group

(C 1 -C 4) alkyl or trifluoromethyl;

. a non-aromatic carbocyclic radical, C3-C12, ⁿ o ⁿ unsubstituted or substituted one or more times with a halogen atom or a (Ci-C4) alkyl, (CJ

C4) alkoxy, hydroxy or cyano; . a (C ₃ -C ₇ ) cycloalkylmethyl group, unsubstituted or substituted on the cycloalkyl by one or more (C 1 -C 4) alkyl groups;

. an aryloxymethyl group unsubstituted or substituted on the methyl by one or two alkyl groups, wherein the term aryloxy represents a phenoxy group unsubstituted or substituted one or more times with Rg;

Ry represents a hydrogen atom or a (C 1 -C 4) alkyl group; Rg represents a halogen atom; a (C 1 -C 4) alkyl group; trifluoromethyl; cyano; (C 1 -C 4) alkoxy; trifluoromethoxy; phenyl; (C3-C7) cycloalkyl or an NHS (O) _n Alk group; n represents 1 or 2; m represents 0, 1 or 2; Alk is (C1-C4) alkyl; in the form of bases or addition salts with acids, as well as with hydrates or solvates.

2. Compounds according to claim 1 of formula (IA), characterized in that Y represents a group -N (Ry) CO-.

3. Compound according to claim 1 of formula (IB), characterized in that Y represents a group -N (Ry) CON (Ry) -.

4. Compound according to claim 1 of formula (IC), characterized in that Y represents a group -OCO-.

5. Compound according to claim 1 of formula (ID), characterized in that Y represents a group -N (Ry) S (O) _n -.

6. Compound according to claim 1 characterized in that:

- R \ represents hydrogen;

and / or R2 and R3 represent a 3 or 4-chlorine atom, a 4-trifluoromethyl group, or two 3 and 4-chlorine atoms; and / or R4 and R5 represent a chlorine atom of 2, 3 or 4, a trifluoromethyl group at 4, or a chlorine atom at 3 and a methyl group at 4.

7. Compound according to any one of claims 2 or 5 characterized in that:

- R \ represents a hydrogen atom;

R2 and R3 represent a 3 or 4-chlorine atom, a 4-trifluoromethyl group, or two 3 and 4-chlorine atoms;

- R4 and R5 represent a chlorine atom in 2, 3 or 4, a trifluoromethyl group in 4, or a chlorine atom in 3 and a methyl group in 4.

Rβ represents a group chosen from:

. a (C 1 -C 6) alkyl group which is unsubstituted or substituted one or more times with one or more substituents chosen independently from a halogen atom or a hydroxy, (C 1 -C 4) alkoxy or trifluoromethoxy group;

. a non-aromatic carbocyclic radical, _C3-Ci2> unsubstituted or substituted one or more times with a halogen atom or a (Ci_C4) alkyl, (C \ - C4) alkoxy, hydroxy or cyano.

8. Compound selected from:

N - ((1- (3,4-dichlorobenzyl) -5- (3,4-dichlorophenyl) -1H-pyrazol-3-yl) methyl) -2,2-dimethylpropanamide;

and N - ((1- (3,4-dichlorobenzyl) -5- (3,4-dichlorophenyl) -1H-pyrazol-3-yl) methyl) -2-methylpropane-2-sulfonamide.

9. Process for the preparation of the compounds of formula (I) according to any one of claims 1 to 8, characterized in that a compound of formula:

in which X represents an oxygen atom, an NH or N (R 7) group and R 1, R 2, R 3, R 4 and R 5 are as defined above for the compounds of formula (I) a) with a functional derivative of an acid of formula RgCOOH (III) in which Rg is as defined above for (I) to obtain a compound of formula (IA) or (IC) in which Y represents the value i) or ii); b) an isocyanate of the formula RgN = C = O (IV) in which Rg is as defined above for (I), to obtain a compound of formula (IB) in which

Y represents the value ii). c) with a halogenated derivative of formula RgS (O) nHal in which HaI represents a halogen atom, preferentially chlorine, and Rg is as defined above for (I), to obtain a compound of formula (ID ) in which

Y is the value iv).

10. Compounds of formula (XII):

in which :

- W represents a hydroxyl or amino group;

R 1 represents a hydrogen atom or a (C 1 -C 4) alkyl group;

R 2 and R 4 each independently represent a hydrogen or halogen atom, or a (C 1 -C 4) alkyl, (C 1 -C 4) alkoxy or trifluoromethyl group;

R 3 and R 5 are each independently of one another a halogen atom or a (C 1 -C 4) alkyl, (C 1 -C 4) alkoxy or trifluoromethyl group, in the form of bases or addition salts to acids, as well as to the state of hydrates or solvates.

11. Medicament, characterized in that it comprises a compound of formula (I) according to any one of claims 1 to 8, or a salt of addition of this compound to a pharmaceutically acceptable acid, or a hydrate or a solvate of the compound of formula (I).

12. Pharmaceutical composition, characterized in that it comprises a compound of formula (I) according to any one of claims 1 to 8, or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, and at least a pharmaceutically acceptable excipient.

13. Use of a compound of formula (I) according to any one of claims 1 to 8 for the preparation of a medicament for the treatment or prevention of diseases in which CB2 cannabinoid receptors are involved.

14. Use of a compound of formula (I) according to any one of claims 1 to 8 for the preparation of a medicament for the treatment and prevention of immune disorders, pain, gastrointestinal disorders, disorders cardiovascular or renal, and / or useful in cancer chemotherapy.